FindTrial
Sign In

Mivelsiran

DRUG3 trials

Sponsors

Alnylam Pharmaceuticals Inc., Alnylam Pharmaceuticals

Conditions

Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brainDown Syndrome-Associated Alzheimer's Disease (DS-AD)Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)causing problems such as bleeding into the brain

Phase 2

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered ALN-APP in Patients with Cerebral Amyloid Angiopathy (CAA)
RecruitingCTIS2023-510137-29-01
Alnylam Pharmaceuticals Inc.causing problems such as bleeding into the brain, Cerebral Amyloid Angiopathy (CAA) is a neurological condition in which amyloid proteins build up in the walls of blood vessels in the brain
Start: 2025-04-09Target: 50Updated: 2025-08-12
A Study to Evaluate Mivelsiran in Adult Participants With Early-Stage Down Syndrome-Associated Alzheimer's Disease (DS-AD)
RecruitingNCT07636811
Alnylam PharmaceuticalsDown Syndrome-Associated Alzheimer's Disease (DS-AD)
Start: 2026-08-17End: 2031-07-23Target: 58Updated: 2026-09-04
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Not yet recruitingCTIS2025-523390-42-00
Alnylam Pharmaceuticals Inc.Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
Target: 14Updated: 2026-07-23